DATATRAK and TAILRD Heart Form Strategic Partnership to Advance AI-Driven Cardiovascular Clinical Research

DATATRAK (搜索)搜索该词条 Powered by Fountayn (搜索)搜索该词条 and TAILRD Heart (搜索)搜索该词条 have announced a strategic collaboration aimed at transforming cardiovascular clinical research through the integration of artificial intelligence and real-world data solutions. The partnership, announced on March 16, 2026, combines TAILRD's AI-powered cardiovascular care platform with DATATRAK's unified eClinical technology platform to enhance clinical trial efficiency and real-world evidence generation.

Strategic Investment and Platform Integration

As part of the collaboration, DATATRAK (搜索)搜索该词条 is making a strategic investment in TAILRD to expand the platform's reach and enable more patients and providers to benefit from AI-powered cardiovascular solutions. The partnership will leverage DATATRAK's comprehensive eSource-enabled eClinical platform, which includes seamlessly integrated eSource, EDC/CDMS, RTSM, CTMS, eTMF, eConsent, and ePRO/eCOA modules within a 21 CFR Part 11, HIPAA, GDPR, and GCP-compliant cloud environment.

TAILRD solutions requiring FDA-regulated clinical trials will utilize this integrated platform, creating a streamlined pathway from AI-driven patient identification to clinical trial execution. The collaboration connects TAILRD's AI-driven cardiovascular analytics and patient-identification capabilities with DATATRAK (搜索)搜索该词条's unified eSource and eClinical platform, enabling more efficient clinical trials and real-world evidence generation across the spectrum of cardiovascular disease (搜索)搜索该疾病.

Comprehensive Cardiovascular Research Solutions

The partnership encompasses multiple facets of cardiovascular care and research, including hospital and physician practice workflows, AI-powered real-world data and real-world evidence generation, virtual and hybrid clinical trials, patient recruitment and pre-screening, and AI-driven cardiovascular knowledge resources designed to provide faster answers for physicians, care teams, and researchers.

"Too many families have been affected by preventable or late-detected cardiovascular disease (搜索)搜索该疾病, and we see a clear opportunity to combine AI, real-world data, and proven clinical trial infrastructure to change that trajectory," said Alex Tabatabai, CEO of DATATRAK (搜索)搜索该词条 Powered by Fountayn (搜索)搜索该词条. "By unifying TAILRD's AI-enabled patient identification and care pathways with our fully integrated eClinical platform, sponsors and health systems can move from insight to action much more quickly."

Addressing Clinical Gaps in Cardiovascular Care

TAILRD, an AI-powered cardiovascular care platform incubated at Mount Sinai Hospital查看公司主页, was developed to address real cardiovascular care gaps across the continuum from early detection to complex interventions and long-term follow-up. The platform transforms how hospitals and health systems identify, treat, and track patients across the full spectrum of heart disease (搜索)搜索该疾病 using structured data, real-world best practices, and AI-driven insights.

"TAILRD was built inside real health systems to solve real cardiovascular care gaps, from early detection to complex interventions and long-term follow-up," said Jonathan Hart, President of TAILRD Heart (搜索)搜索该词条. "Partnering with DATATRAK (搜索)搜索该词条 gives us a powerful, scalable trial and data backbone so that the same infrastructure improving day-to-day patient care can also power the next generation of cardiovascular research and therapies."

Platform Capabilities and Clinical Impact

TAILRD delivers modular, evidence-based solutions that integrate into existing clinical workflows, helping care teams scale guideline-directed care, reduce variability, and unlock new clinical and financial value. In collaboration with research partners and life sciences sponsors, TAILRD supports clinical trials by identifying qualified patients, streamlining site activation, and accelerating enrollment.

DATATRAK (搜索)搜索该词条 brings extensive cardiovascular research experience, having supported complex studies with leading cardiovascular CROs and institutions. The company's EDC/CDMS technology, first established in 1991, has a proven track record of supporting complex studies that have achieved regulatory approvals and is validated to meet FDA CFR 21 Part 11, HIPAA, GDPR, and GCP requirements.

Both organizations share a mission to improve cardiovascular health outcomes globally and reduce the burden of heart disease (搜索)搜索该疾病, recognized as one of the world's leading causes of morbidity and mortality. The collaboration aims to accelerate the development and delivery of evidence-based therapies while helping health systems improve cardiovascular outcomes at scale.